公开(公告)号：US20250073219A1

公开(公告)日：2025-03-06

申请号：US18567452

申请日：2022-06-10

Applicant: NANEXA AB

Inventor： Joel HELLRUP ,  Jonas FRANSSON ,  Mårten ROOTH ,  Anders JOHANSSON ,  David WESTBERG ,  Erik LINDAHL

IPC: A61K31/454 ,  A61K9/50

Abstract: The invention relates to a plurality of coated particles containing a solid core containing one of the compounds lenalidomide and pomalidomide, or a pharmaceutically acceptable salt thereof. The core has a mean diameter of the between 0.1 pm and 50 pm. The core is a coated by a coating surrounding, enclosing and/or encapsulating the core. The coating contains a mixed oxide selected from the group consisting of iron oxide, zinc oxide, silicon oxide, titanium oxide, and aluminium oxide.

公开(公告)号：US20240277624A1

公开(公告)日：2024-08-22

申请号：US18568363

申请日：2022-06-10

Applicant: NANEXA AB

Inventor： Anders JOHANSSON ,  Mårten ROOTH ,  Erik LINDAHL ,  Joel HELLRUP ,  Jonas FRANSSON ,  David WESTBERG ,  Otto SKOLLING

IPC: A61K9/50 ,  A61K9/00 ,  A61K9/10 ,  A61K9/51 ,  A61K38/00 ,  C23C16/40 ,  C23C16/44 ,  C23C16/455

CPC classification number: A61K9/5073 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/501 ,  A61K9/5115 ,  C23C16/407 ,  C23C16/4417 ,  C23C16/45555 ,  A61K38/00

Abstract: There is provided a pharmaceutical formulation that is useful in delivering a biologic active drug in a high dose, comprising a plurality of particles suspended in an aqueous carrier system, which particles: pharmaceutical formulation, comprising a plurality of particles suspended in a carrier system, which particles: (a) have a weight-, number-, or volume-based mean diameter that is between amount 10 nm and about 700 pm; and (b) comprise solid cores comprising a biologic active drug, coated, at least in part, by a coating of inorganic material, and wherein the formulation comprises a concentration of said biologic active drug of at least 10 mg/ml. Preferred biologic active drug include immunoglobulins, monoclonal antibodies, antibody mimetics, cytokines and cytokine antagonists, and human peptide hormones.

公开(公告)号：US20240261228A1

公开(公告)日：2024-08-08

申请号：US18567466

申请日：2022-06-10

Applicant: NANEXA AB

Inventor： Anders JOHANSSON ,  Mårten ROOTH ,  Erik LINDAHL

IPC: A61K9/50 ,  A61K31/405 ,  A61K31/706

CPC classification number: A61K9/5089 ,  A61K9/501 ,  A61K31/405 ,  A61K31/706

Abstract: There is provided a process for the preparation of composition in the form of a plurality of particles having a weight-, number-, and/or volume-based mean diameter that is between amount 10 nm and about 700 μm, which particles comprise: (a) solid cores, preferably comprising a biologically active agent; and (b) two or more sequentially applied, discrete layers, each of which comprises at least one separately applied coating material, and which two or more layers together surround, enclose and/or encapsulate said cores, which process comprises the sequential steps of: (1) applying an initial layer of at least one coating material to said solid cores by way of a gas phase deposition technique; (2) subjecting the coated particles to agitation to deagglomerate particle aggregates formed during step (1) by way of a sieving step; (3) applying a further layer of at least one coating material to the deagglomerated particles; and (4) optionally repeating steps (2) and (3) one or more times to increase the total thickness of the at least one coating material that enclose(s) said solid core, wherein at least one of the sieving steps comprises a vibrational sieving technique, in which the vibrational sieving technique comprises supplying electrical power to a vibration motor coupled to a sieve. The gas phase deposition technique is preferably atomic layer deposition. When the cores comprise biologically active agent, the compositions may provide for the delayed or sustained release of said active agent without a burst effect.

公开(公告)号：US20240277749A1

公开(公告)日：2024-08-22

申请号：US18568219

申请日：2022-06-10

Applicant: NANEXA AB

Inventor： Anders JOHANSSON ,  Mårten ROOTH ,  Erik LINDAHL ,  Joel HELLRUP ,  David WESTBERG

IPC: A61K31/706 ,  A61K9/00 ,  A61K9/10 ,  A61K9/50 ,  A61P35/00 ,  C23C16/40 ,  C23C16/455

CPC classification number: A61K31/706 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/501 ,  A61K9/5073 ,  A61P35/00 ,  C23C16/407 ,  C23C16/45555

Abstract: There is provided a pharmaceutical formulation that is useful in the treatment of myelodysplastic syndrome, comprising a plurality of particles suspended in an aqueous carrier system, which particles: (a) have a weight-, number-, or volume-based mean diameter that is between amount 10 nm and about 700 μm; and (b) comprise solid cores comprising azacitidine, or a pharmaceutically-acceptable salt thereof, coated, at least in part, by a coating of inorganic material comprising mixture of: (i) zinc oxide; and (ii) one or more other metal and/or metalloid oxides, wherein the atomic ratio ((i):(ii)) is between at least 1:6 and up to and including about 6:1. Said mixed oxide coated particles are preferably synthesized via a gas phase coating technique, such as atomic layer deposition. The formulation may provide for the delayed or sustained release of azacitidine to treat myelodysplastic syndrome without a burst effect.